<DOC>
	<DOCNO>NCT00697632</DOCNO>
	<brief_summary>In study , MGCD265 , new anticancer drug investigation , give daily patient advanced malignancy study safety profile .</brief_summary>
	<brief_title>Safety Study Oral MGCD265 Administered Without Interruption Subjects With Advanced Malignancies</brief_title>
	<detailed_description>MGCD265 belong new class drug anticancer potential , know tyrosine kinase inhibitor . MGCD265 show slow growth human cancer cell mice . Clinical study pursue evaluate safety MGCD265 cancer patient . In study , MGCD265 orally administer daily basis patient advanced malignancy .</detailed_description>
	<criteria>Advanced metastatic unresectable malignancy refractory standard therapy and/or exist therapy likely achieve clinical benefit , and/or patient decline receive standard treatment chemotherapy . Evaluable disease ; Last dose prior chemotherapy , radiation therapy , investigational agent occur least 4 week start therapy ; Recovery adverse effect â‰¤ grade 1 ; Acceptable ECOG status 0 , 1 , 2 ; Life expectancy great 3 month follow study entry ; Adequate laboratory value ; For patient enrol four expansion cohort : NSCLC patient must meet criterion MET and/or Axl expression , HNSCC patient must meet criterion MET and/or Axl expression , NSCLC patient must meet criterion amplification MET gene locus , define MET mutation , rearrangement involve AXL MET gene locus ; Patients tumor type HNSCC , papillary renal carcinoma , gastric adenocarcinoma , solid tumor must meet criterion amplification MET gene locus , define MET mutation , rearrangement involve AXL MET gene locus Uncontrolled concurrent illness ; History cardiovascular illness ; QTc &gt; 470 msec ( include subject medication ) ; Left ventricular ejection fraction ( LVEF ) &lt; 50 % ; Immunocompromised subject ; History bone marrow transplant ; Lung tumor lesion increase likelihood bleeding ; Symptomatic uncontrolled brain metastasis ; Unable swallow oral medication preexist gastrointestinal disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MET</keyword>
	<keyword>AXL</keyword>
	<keyword>VEGFR</keyword>
	<keyword>NSCLC</keyword>
	<keyword>HNSCC ( Head neck squamous cell carcinoma )</keyword>
	<keyword>Tumor</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Solid tumor</keyword>
</DOC>